HPV阴性头颈癌中微小淋巴结外侵犯的意义及辅助放化疗作用
本研究基于美国国家癌症数据库2009至2015年数据,纳入5483例pN+ HPV阴性头颈鳞癌根治性术后患者,其中24%存在微小淋巴结外侵犯(ENEmi)。多因素分析显示ENEmi与总生存(OS)下降独立相关(aHR=1.43,95%CI 1.28-1.59);在ENEmi且接受≥60 Gy辅助放疗的617例患者中,同步放化疗较单纯放疗未改善OS(aHR=0.91,95%CI 0.66-1.27)。结论提示ENEmi为不良预后因素,但辅助同步放化疗对该人群的生存获益尚不明确。
要点
- pN+ HPV阴性HNSCC中ENEmi发生率24%,与OS显著下降相关。
- ENEmi患者接受≥60 Gy放疗时,同步化疗未显著改善OS。
- ENEmi的最佳辅助治疗模式仍需进一步研究。
核心结论
- pN+ HPV阴性HNSCC中,ENEmi与较无ENE者更差的总生存独立相关。
- 对于ENEmi患者,辅助同步放化疗较单纯放疗未显著改善总生存。
研究设计与样本
- 回顾性队列研究,数据来自美国国家癌症数据库2009至2015年。
- 纳入5483例pN+ HPV阴性HNSCC且接受切缘阴性手术的患者。
主要发现
- 5483例中24%存在ENEmi。
- 多因素分析显示ENEmi与OS下降相关(aHR=1.43;95%CI 1.28-1.59)。
- ENEmi且接受≥60 Gy辅助放疗者617例,同步放化疗较放疗的OS无显著改善(aHR=0.91;95%CI 0.66-1.27)。
临床怎么用
- 对pN+ HPV阴性HNSCC术后病理应关注ENEmi状态以评估预后。
- ENEmi患者选择辅助同步放化疗需个体化, current证据未显示明确OS获益。
局限性
- 回顾性队列研究,存在选择偏倚可能。
- 数据源自国家癌症数据库,部分变量信息可能受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Pathologic extranodal extension (ENE) is an important adverse feature for human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC), but the prognostic significance of microscopic ENE (ENEmi) and role of adjuvant concurrent chemoradiation (CRT) for ENEmi remain unclear. This study evaluates (1) the prognostic significance of ENEmi in HPV-negative HNSCC and (2) whether adjuvant CRT is associated with improved overall survival (OS) for these patients. STUDY DESIGN: Retrospective cohort study. SETTING: Commission on Cancer (CoC)-accredited facilities. METHODS: This retrospective cohort study included patients in the National Cancer Database from 2009 to 2015 with pathologic node-positive (pN+) HPV-negative HNSCC with either pathologic ENEmi or no ENE who had undergone margin-negative surgery. The association of ENEmi with OS was evaluated using Cox proportional hazard analyses. Analyses were repeated in patients with ENEmi receiving adjuvant therapy to evaluate the association of adjuvant CRT with OS. RESULTS: We included 5483 patients with pN+ HPV-negative HNSCC, of whom 24% had ENEmi. On multivariable analysis, ENEmi was associated with decreased OS relative to no ENE (adjusted hazard ratio [aHR], 1.43; 95% CI, 1.28-1.59). Among patients with ENEmi who received ≥60 Gy of adjuvant radiation therapy (RT) (n = 617), adjuvant CRT was not associated with improved OS relative to RT (aHR, 0.91; 95% CI, 0.66-1.27). CONCLUSION: For patients with HPV-negative HNSCC, pN+ with ENEmi is associated with worse OS than pN+ without ENE. However, for patients with ENEmi, concurrent CRT is not associated with improved OS relative to RT. The optimal adjuvant paradigm for ENEmi requires additional investigation.
引用
- Yan F, Li H, de Almeida JR, et al. Microscopic Extranodal Extension in HPV-Negative Head and Neck Cancer and the Role of Adjuvant Chemoradiation. Otolaryngol Head Neck Surg. 2021. PMID: 33618570. doi:10.1177/0194599821989637
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。